


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/825,923
Filing Date	04/15/2004
First Named Inventor	Simon Bailey
Art Unit	1814 1626
Examiner Name	Andrew Freisten
Attorney Docket Number	PC25631A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>2</sup> Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
AB	AA	JP7-316144	12-05-1995	Sankyo Co. Ltd.		
		<del>WO 02/098840</del>				
	AB	(including English Abstract)	12-12-2002	Eisai Co., Ltd.		
AC	AC	EP1394147 (Equivalent to WO 02/098840)	03-03-2004	Eisai Co., Ltd.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AD	AD	DENMARK, et al., "(E)-3-(Trimethylsilyl)-2-propen-1-ol. An Improved Preparation," <i>Journal of Organic Chemistry</i> , 1982, 4595-4597, Vol. 47.	
AE	AE	DORLAND, et al., <i>Dorland's Illustrated Medical Dictionary</i> , 2000, 29 <sup>th</sup> Edition, 555 and 755, W. B. Saunders Company, Philadelphia.	
AF	AF	GEARING, et al., "Interaction of the Peroxisome-proliferator-activated Receptor and Retinoid X Receptor," <i>Proceedings of the National Academy of Science, USA</i> , 1993, 1440-1444, Vol. 90.	
AG	AG	HEYMAN, N., et al., "9-cis Retinoic Acid is a High Affinity Ligand for the Retinoid X Receptor," <i>Cell</i> , 1992, 397-406, Vol. 68.	

EXAMINER:

Andrew Freisten

DATE CONSIDERED:

1-3-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

★ Not in English

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.













Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**


(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/825,923
Filing Date	04/15/2004
First Named Inventor	Simon Bailey
Art Unit	<del>1814</del> 16-26
Examiner Name	<del>FBA</del> Andrew Freisler
Attorney Docket Number	PC25631A

	AH	INUI, S., et al., "Synthesis and Thermal Properties of Antiferroelectric Liquid Crystals Having Phenylalkanoate and Phenylalkenoate Moieties," <i>Mol. Cryst. Liq. Cryst. Sci. Technol. Sect. A.</i> , 1994, 1-10, Vol. 239.	
	AI	ISSEMAN, N. et al., "Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators," <i>Nature</i> , 1990, 645-650, Vol. 347.	
	AJ	KELLER, et al., "Fatty Acids and Retinoids Control Lipid Metabolism Through Activation of Peroxisome Proliferator-activated Receptor-retinoid X Receptor Heterodimers," <i>Proceedings of the National Academy of Science USA</i> , 1993, 2160-2164, Vol. 90.	
	AK	KLIEWER, et al., "Convergence of 9-cis Retinoic Acid and Peroxisome Proliferator Signalling Pathways through Heterodimer Formation of their Receptors," <i>Nature</i> , 1992, 771-774, Vol. 358.	
	AL	LEVIN, et al., "9-Cis Retinoic Acid Stereoisomer Binds and Activates the Nuclear Receptor RXR $\alpha$ ," <i>Nature</i> , 1992, 359-361, Vol. 355.	
	AM	PATINI, et al., "Bioisosterism: A Rational Approach In Drug Design," <i>Chemical. Reviews</i> , 1996, 3147-3176, Vol. 96.	
	AN	REDDY, et al., "Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans," <i>Critical Reviews in Toxicology</i> , 1983, 1-58, Vol. 12, No. 1.	
	AO	SCHOW, et al., "Diastereoselective Synthesis of the Antibiotic L-Azatyrosine," <i>Journal of Organic Chemistry</i> , 1994, 6850-6852, Vol. 59.	
	AP	STEDMAN, et al., <i>Stedman's Medical Dictionary</i> , 26th Edition, Williams & Wilkins, Baltimore.	
	AQ	THAVONEKHAM, B., et al., "A Practical Synthesis of Ureas from Phenyl Carbamates," <i>Synthesis</i> , 1997, 1189-1194, Vol. 10.	
	AR	TOMASSY, et al., "Stereoselective Routes to E and Z Straight-Chain Primary Allylic Amines," <i>Synthetic. Communications</i> , 1998, 1201-1214, Vol. 28, No. 7.	
	AS	VAN BENTHEM, et al., "A Practical Synthesis of Geometrically Pure N-Boc-Protected Primary Allylic Amines," <i>Synlett Letters</i> , 1994, 368-370.	

EXAMINER:



DATE CONSIDERED:

1-3-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*\*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/825,923
Filing Date	04/15/2004
First Named Inventor	Simon Bailey
Art Unit	1626
Examiner Name	Andrew B. Freistein
Attorney Docket Number	PC25631A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
<i>AB</i>	AA	WO 02/064130	08-22-2002	Pfizer Products Inc.		
<i>AB</i>	AB	EP-A-1 088 284	04-04-2001	Pfizer Products Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

EXAMINER:

*Andrew Freistein*

DATE CONSIDERED:

*1-3-06*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.